1 Abbreviations used in this paper: BMLA, bone marrow lymphocyte antigen; CFU-S, spleen colony-forming unit (used synonymously with pluripotent hemopoietic stem cell); FACS, fluorescent-activated cell sorter; FITC, fluorescein-conjugated; null, lacking T-and B-cell antigenic markers; RITC, tetramethyl rhodamine conjugated; TdT, terminal deoxynucleotidyl transferase. The preparation and absorption of the rabbit antiserum to the Thy-1 molecule purified from rat brain is described in full elsewhere. 8 Of the anti-Thy-1 antibodies in this serum, 51% recognized the rat-specific xenoantigenic determinant, 41% recognized the rat-mouse crossreacting xenoantigenic determinant, and approximately 8% recognized the Thy-1.1 alloantigenic determinant (assayed as in [8] ). The IgG fraction from this serum was prepared by Na2SO4 precipitations, DEAE-Sephadex ion exchange chromatography, and Sephadex G-200 gel filtration following standard procedures. The F(ab')2 fragments prepared from this (32) were conjugated with fluorescein isothiocyanate (Baltimore Biological Laboratories, Cockeysville, Md.) as described by The and Feltkamp (33) . Antibodies with a fluorescein/protein molar ratio of between 1.0 and 3.4 were pooled, giving a mean fluorescein/protein ratio of 1.7 for the preparation. This rabbit anti-Thy-1 antiserum is referred to as serum number 1 in the text.
The F(ab')2 of a second rabbit antiserum to rat brain Thy-1 was used for fluorescence microscopy. This serum, the gift of Dr. A. F. Williams (Oxford University), was absorbed for 1 h at 4°C with 3 × l0 s rat spleen cells and 6 × l0 s rat lymph node cells per ml of antiserum. The IgG fraction was isolated, from which the F(ab')2 was prepared. Of its anti-Thy-1 antibodies, 45% recognize the rat-specific Thy-1 xenoantigenic determinant, 37% recognize the rat-mouse cross-reacting xenoantigenic determinant, and 18% recognize the Thy-1.1 alloantigenic determinant (10) . This rabbit anti-Thy-1 antiserum is referred to as serum 2 in the text.
Rabbit F(ab')2 anti-mouse-IgG purified antibodies, and horse F(ab')~ anti-rabbit IgG purified antibodies, were the gift of Dr. A. F. Williams (Oxford University). Fluorescein-conjugated (FITC) goat anti-rabbit IgG and tetramethyl-rhodamine conjugated (RITC) goat anti-mouse IgG were obtained from Cappel Laboratories, Inc., Cochranville, Pa.). The latter antiserum was passed down a normal rat serum Sepharose 4B affinity column (serum at 10 mg/ml coupled to cyanogen bromide-activated Sepharose 4B) (Pharmacia Fine Chemicals, N.J.) to remove cross-reacting antibodies to rat immunoglobulins.
Protein determinations were done by the method of Lowry et al. (34) using bovine serum albumin (Sigma Chemical Co., St. Louis, Mo., Fraction V) as a standard.
Quantitative Absorptions of Antisera. Antisera were absorbed with deoxycholate-free purified Thy-1 by incubating (at 4°C) twofold serial dilutions of the antigen (in 125 #l of Tyrode's buffer with a starting concentration of 43.5 #g/ml) with an equal volume of antiserum (see Results for dilutions used). After 30 min (for immunofluorescence) or 20 h (for opsonization and quantitative radioactive binding assay), the residual titer or antibody binding was assayed and compared to that of the unabsorbed serum to which only buffer had been added. Absorption of antiserum with brain and liver homogenate (prepared as [8] ) was performed by similar 30-min incubations of serial twofold dilutions of the tissue homogenate (initial concentration of 20 mg protein/ml) with equal volumes of antiserum. After centrifugation (3,000 g, 10 min) the residual antibody activity was assessed by immunofluorescence.
Indirect Radioactive Binding Assays. These were used to give a quantitative measure of antibody binding to thymocytes after inhibition of the rabbit IgG anti-rat brain Thy-1 antigen by Thy-1 antigen, and have been described (8) .
Immunofluorescence. Indirect immunofluorescence was performed on frozen sections and on cell suspensions as described previously (30, 35) .
Simultaneous immunofluorescence with rabbit and mouse antisera was performed as follows: cells in suspension were incubated with the first antiserum (20 min, 4°C, 10 mM NAN,), washed, incubated with the second antiserum (20 rain, 4°C, 10 mM NaNa), washed and incubated sequentially with FITC-labeled goat anti-rabbit IgG (dilution 1:20) and FITClabeled goat anti-mouse IgG (dilution 1:10). Routine controls included incubating the two antisera in reverse sequence, substituting normal rabbit and/or mouse serum for one or both antisera; and reacting the FITC and RITC conjugates against cells coated with antiserum from the inappropriate species (i.e. mouse instead of rabbit and vice versa).
Cocapping experiments using rabbit and mouse antisera were performed as follows. Cells in suspension were incubated with the first antiserum (20 min, 4°C) and developed with the appropriate conjugated antiserum under capping conditions (30 min, 37°C). The cells were washed in cold buffer containing 10 mM NaNs, checked for capping, and smeared on glass slides in a cytocentrifuge (Shandon Southern Instruments, Inc., Sewickley, Pa.). The cells were then incubated with the second antiserum (20 rain, 21°C), washed, and developed with the second conjugated antiserum. In a variation of this procedure, cells were incubated with the with 0.12-1.9 #g fluorescein-conjugated rabbit F(ab')2 anti-rat brain Thy-1 antibodies in 0.25 ml Eisen's balanced salt solution. The cells were washed three times in buffer and diluted to a concentration of 5 X 10 s ceils/ml for sorting on the FACS. Erythrocytes were gated electronically according to their distribution profile under 0°C light scatter, using a threshold that excluded fewer than 2% of nucleated bone marrow cells (Fig. 1 A) . The nucleated cells were sorted into Thy-1-positive and Thy-1-negative populations according to intensity of fluorescence as described under Results and Fig. 1 B.
Antibody Treatment of Donor Cells. Sensitization of donor cells with antibody was conducted as described previously (26) . Briefly, 1 × 106-1 × 10 s donor cells were incubated for 20 min at 4°C with 0.05 ml of appropriately diluted rabbit or mouse anti-Thy-l.1 serum or normal serum. The treated cells were washed twice in cold Tyrode's solution, checked for viability by trypan blue dye exclusion, and diluted for injection. The presence of mouse or rabbit immunoglobulin on the treated rat cell was verified by indirect immunofluorescence.
Spleen Weight and CFU-S Assays. 1 × 106-1 × 10 s antibody-treated adult rat bone marrow, neonatal spleen, or fetal liver cells in 1.0 ml Tyrode's solution were injected i.v. into syngeneic rats that had received 800 rads whole body X-irradiation 2 h previously. 0.4 × 106-1 × 106 FACS separated adult rat bone marrow cells in 1.0-2.0 ml Eisen's balanced salt solution were injected i.v. into syngeneic rats that had received 750 rads whole body X-irradiation 6 h previously. The recipients were sacrificed 12 days after injection. The spleens were weighed, fixed, and examined for macroscopically visible colonies (26) . Selected spleens were embedded in paraffin, sectioned, and stained with hematoxylin and eosin for microscopic examination of spleen colony morphology.
Complement-Mediated Cytotoxicity. 2.5 × 10 ~ nucleated rat bone marrow, thymus, spleen, or lymph node cells in 25 #I Dulbeeco's phosphate-buffered saline plus 10 mM NaNa were incubated (30 min, 4°C:) with 50 #1 appropriately diluted antiserum or normal serum. Cells were then washed once and incubated for 60 min at 37°C with 0.1 ml complement (normal Lewis rat serum). Viability counts were performed by trypan blue dye exclusion. The specificity and extent of the killing, as compared to the normal serum control, was confirmed by examination of the surviving cells by immunofluorescenee (27) .
Results

Distribution of Thy-l-Positive Cells in Rat Lymphohemopoietic
Tissues. The distribution of putative Thy-l-positive cells in the lymphohemopoietic tissues of normal rats is shown in Table I . The highest percentages of positive cells are found in bone marrow, thymus and spleen; the lowest percentages are in lymph node, blood, and thoracic duct lymph. The same proportions of positive cells were obtained in indirect immuno fluorescence assays and in complement-mediated cytotoxicity assays using two different lots of rabbit anti-rat brain Thy-1 serum (Materials and Methods).
In frozen sections of rat thymus the rabbit F(ab')2 anti-Thy-1 antibodies (serum 2) labeled cortical thymocytes much more intensely that it did medullary thymocytes. Consistent with this was the finding that strongly Thy-l-positive thymocytes are sensitive to cortisone. The 53% reduction produced by this steroid in the proportion of Thy-l-positive thymoeytes (Table I) represents an absolute decrease of 92% in the total number of Thy-1-positive cells. Thy-1-positive cells in bone marrow and spleen are similarly sensitive to cortisone (Table I) .
Inhibition of the Binding of Rabbit IgG Anti-Rat Brain Thy-I to Thymocytes.
To assess the specificity of the reaction of the rabbit anti-rat brain Thy-1 antiserum, the binding of a constant amount (1.5 #g) of the IgG fraction of this antiserum (serum 1) to rat thymocytes was inhibited by a prior incubation of the antibody with serial twofold dilutions of pure Thy-1 antigen. More than 90% of the inhibition occurred in the range of 2-10 ng of Thy-1 antigen; and 25 ng reduced binding to the background level. It can be seen in Fig. 2 that the inhibition occurs steeply around the equimolar ratio of antigen to antibody. Two probable sources of error in the calculation of the amount of Thy-1 antigen should be noted. This was estimated by the Lowry et al. method (34) for protein determination, using bovine serum albumin as the standard. The latter protein has 1.68 the tyrosine content of Thy-1 (37, 38) (the major amino acid measured in this protein determination); moreover bovine serum albumin is not a glycoprotein, whereas 29% by weight of rat brain Thy-1 is carbohydrate whose mass is obviously not assayed in the protein determination. Both these sources of error would lead to an underestimate of the true amount of Thy-1, by as much as 2.4-fold in all, so that the antigen: antibody ratio in Fig. 2 almost certainly underestimates the true ratio, possibly by as much as this factor. Table II show that the rabbit anti-Thy-1 antiserum (serum 1) in dilutions from 1:I00 to 1:5,000, was able to completely abrogate the spleen CFU-S activity of adoptively transferred adult rat bone marrow cells. 50% inhibition of CFU-S activity was observed at a 1:10,000 dilution of the antiserum. A similar degree of inhibition by the antiserum of the ability of bone marrow ceils to increase spleen weight in irradiated recipients was observed. Prior absorption of the antiserum with pure rat brain Thy-1 antigen removed the ability of the antiserum to inhibit CFU-S activity and to prevent spleen weight gain. Allowing for the 1.8-fold larger vol and 4.9-fold higher concentration of the antiserum used in this assay, 0.33 #g Thy-1 used here is equivalent to 37 ng used in Fig. 2 , or an antigen: antibody molar ratio of 1.9.
TABLE I
Distribution of Thy-l-Positive Cells in Rat Lymphohemopoietic Tissues
Effect of Rabbit Anti-Rat Brain Thy-1 Antiserum on CFU-S in Bone Marrow. Results in
Further evidence of the specificity of the reaction against stem cells was obtained using two murine anti-Thy-l.1 alloantisera. AKR/Cum anti-AKR/Jax thymoeyte antiserum (dilution 1:20) was found to completely inhibit CFU-S activity in adult rat bone marrow. This inhibition was prevented by prior absorption of the antiserum with purified rat brain Thy-I antigen, or with AKR/Jax (Thy-l.1 type) but not AKR/Cum (Thy-l.2 type) brain homogenates. CBA mouse anti-AKR mouse thymocyte serum (dilution 1:20) was similarly effective in inhibiting the CFU-S activity of adult rat bone marrow. Table   IIIa the increase in spleen weight and number of spleen colonies after injection of increasing numbers of spleen cells from 3-day-old rats is shown. Incubation of the highest number of cells used (10 T ) with increasing dilutions of rabbit anti-rat brain Thy-1 serum inhibited the CFU-S activity as assessed by both parameters (Table  IIIb) . An approximately fourfold higher concentration of antiserum than that required for the adult bone marrow cells was needed for comparable inhibition, reflecting the larger cell inoculum used and higher proportion ofThy-l-positive cells in the neonatal spleen.
Effect of Anti-Thy-1 Antiserum on CFU-S in Neonatal Spleen and Fetal Liver. In
The mean spleen weights obtained with increasing numbers of neonatal spleen cells, and with 107 spleen cells treated with various dilutions of anti-Thy-1 antiserum, are plotted in Fig. 3 . It can be seen that not only is the relationship of spleen weight to numbers of injected cells approximately linear, so also is the abrogation of this activity by anti-Thy-l-serum. Moreover, the dose-response curves are virtually coincidental,
The rabbit anti-rat brain serum was similarly effective in eliminating CFU-S activity in 16 day fetal rat liver.
CFU-S Activity in Thy-l-Positive and Thy-l-Negative Populations of Bone Marrow Cells Separated by the Fluorescence-Activated Cell Sorter (FACS). Bone marrow cells from young
adult DA strain rats were incubated in vitro with fluorescein-conjugated rabbit F(abl)~ anti-rat brain Thy-1 antibodies (serum 1). Thy-1-positive and Thy-1-negative populations of nucleated cells were separated on the FACS. Almost complete separation (>98% purity) of these populations was possible because of the sharp bimodality of fluorescence intensity (Fig. 1) .
Between 38.5 and 49.0% (mean 44.9%) of nucleated bone marrow cells were Thy-1 positive by FACS analysis. 4 The percentage of Thy-l-positive cells was constant at antibody concentrations of 0.5-7.5/zg protein/ml/8 X 108 nucleated cells. Antibody activity was reduced to background levels by absorption with rat thymoeytes.
Results in Table IV show that all CFU-S in DA rat bone marrow are Thy-1 positive. In a series of four experiments using FACS separated cells, 1 X 10 n Thy-1-positive bone marrow cells produced a mean of 59.6 hemopoietic colonies in the spleens of irradiated recipients; whereas 1 × 106 antibody-treated but unseparated bone marrow cells, containing a mean of 40.1% Thy-1-positive cells, produced a mean of 25.3 spleen colonies. This represents a 2.6-fold enrichment in CFU-S activity (or 100% recovery) when the data are corrected for a mean of 3.3 endogenous colonies. In contrast, 1 × 108 FACS separated Thy-l-negative cells failed to produce spleen colonies above background levels.
Complete recovery of CFU-S activity in the Thy-l-positive cell fraction was also obtained with FACS separated Lewis strain (two experiments) and Wistar strain (one experiment) rat bone marrow cells.
In another series of experiments, Thy-l-positive cells were sorted on the FACS according to relative fluorescence intensity. More than 90% of CFU-S activity was recovered within the upper 25th percentile of fluorescent cells.
In none of the above experiments did the F(abl)2 anti-Thy-I antibodies, used at a concentration of 1.9/~g/ml/8 X l0 s nucleated bone marrow cells, alter the ability of CFU-S to migrate to spleen and to form hemopoietic colonies there (compare antibody-treated to untreated bone marrow cell controls in Table IV) . However, antibody concentration of 7.5 ~tg/ml/8 X 108 cells caused an approximately 50% decrease in the number of spleen colonies, due at least in part to agglutination of Thy-1-positive cells.
Relation of the Thy-1 Antigen to the Rat BMLA. In the rat (5, 6, and this paper) and the mouse (data not shown) the same proportions of thymus, spleen, lymph node, and bone marrow cells that react with anti-Thy-1 serum also react with antiserum to the Table III. bone marrow lymphocyte antigen (anti-BMLA) (27) . Both antisera have been shown to abrogate CFU-S activity in adult rat bone marrow (26, and this paper).
That the Thy-1 and BMLA antigenic determinants are present on the same TASLE IV molecule was demonstrated by double immunofluorescence in which the appropriate fluorescein-and rhodamine-conjugated antisera were used simultaneously to detect both antigens (Materials and Methods). All rat thymocytes and bone marrow cells which had Thy-l.1 antigen also had BMLA, and vice versa. Moreover, capping of either of these antigens with its appropriate antiserum caused the capping of the other antigen. Results of an experiment with thymocytes are presented in Table V ; similar results were obtained with bone marrow cells. As a control for the specificity of the cocapping phenomenon, rabbit anti-T-ceU serum (absorbed with rat bone marrow cells) was substituted for anti-BMLA in the above system. Although the anti-T-cell serum caused complete capping of the relevant T-cell antigen(s) on thymocytes, cocapping with Thy-l.1 antigen did not occur. Conversely, capping with anti-Thy-1.1 serum did not cause cocapping of antigen(s) detected by the anti-T-cell serum.
CFU-S Activity m Thy-l-Positive and Thy-l-Negative Populatwns of DA Rat Bone Marrow Cells Separated by the FACS
The conclusion that Thy-1 and BMLA are on the same molecule was further substantiated by the following observations. Binding of anti-BMLA serum to rat bone marrow, thymus, and spleen cells was completely prevented by absorption with small quantities of rat or AKR/J mouse brain homogenate. Anti-BMLA serum was neutralized by purified Thy-1 antigen used at the minimum concentration required to neutralize rabbit anti-Thy-1 serum of equal titer.
Discussion
We have used three experimental approaches to demonstrate that Thy-1 antigen is present on pluripotent stem cells in rat hemopoietic tissues: (a) depletion of Thy-1-positive cells by treatment with anti-Thy-1 antibodies; (b) isolation of Thy-l-positive and Thy-1-negative cells by the FACS; and (c) demonstration that Thy-1 and BMLA antigens are present on the same molecule. The CFU-S assay was used to specifically identify and quantify pluripotent stem cells. This assay detects clones of erythrocytic and myelocytic cells that are formed by individual stem cells; the number of colonies formed being a linear function of the number of hem0poietic cells injected. A derivative assay, the spleen weight assay, was used as a general measure of hemopoietic regenerative capacity.
Rabbit antiserum to purified rat brain Thy-1 molecule was used in the first set of experiments. The CFU-S activity of adult bone marrow was completely abrogated by dilutions of antiserum up to 1:5,000; and 50% inhibition was observed at 1:10,000. At such dilutions it seems unlikely that any antibodies except those to the Thy-1 antigen could be responsible. Moreover, this inhibition was completely neutralized by purified rat brain Thy-1 antigen, used here at antigen: antibody molar ratios of as little as 1.9:1. Other evidence of the specificity of the anti-Thy-1 serum was provided by antibody binding studies using thymocytes as target cells. Inhibition of antibody binding by purified rat brain Thy-1 antigen occurred steeply around the equimolar antigen: antibody range. Under these conditions, any minor contaminants of the purified antigen which might have escaped detection on the sodium dodecyl sulfate polyacrylamide gels could not have inhibited the action of the anti-Thy-1 serum.
The conclusion that the effect of the rabbit antiserum on rat CFU-S activity Was specifically mediated by anti-Thy-1 antibodies was further substantiated by using two murine anti-Thy-1 alloantisera. The first of these, the AKR/Cum anti-AKR/J thymocyte serum, is raised between two mouse strains for which Thy-1 is the only known cell surface antigenic difference (39) . That the abrogation of CFU-S activity was due to anti-Thy-1.1 antibodies in this serum was demonstrated by the neutralization of this effect by the rat brain Thy-1 antigen, and by absorption of the antiserum with the brain homogenate from the Thy-1.1 but not the Thy-l.2 type mouse strain. The second anti-serum, CBA anti-AKR thymocyte serum, which has been shown to only recognize the Thy-1.1 antigen on rat thymocytes by absorption with tissues from Thy-1 congenic mouse strains (31) , was equally effective in abrogating the CFU-S activity of adult rat bone marrow cells.
Additional evidence for the presence of Thy-1 antigen on hemopoietic stem cells is the finding that rabbit antiserum raised against a population of lymphocyte-like null cells from rat bone marrow (anti-rat bone marrow lymphocyte antigen serum; anti-BMLA serum) (27) reacts with Thy-1 antigen. Anti-BMLA serum has already been shown to eliminate CFU-S activity in adult rat bone marrow (26) . Here we show that BMLA and Thy-1.1 occur on the same cells in rat bone marrow, and that antiserum to either antigen causes a redistribution (capping) of both antigens to the same area of the cell. Such cocapping has only been observed for antigens which are physically linked, such as/0-2 microglobulin and HLA on human lymphocytes (40) . Since the purified rat brain Thy-1 antigen fully inhibits the binding of anti-BMLA to rat lymphocytes, this physical linkage of the two antigens must be by virtue of their being determinants on the same Thy-1 molecule.
It is clear from the preceding experiments that anti-Thy-1 sera, raised by diverse methods, can completely abrogate CFU-S activity in suspensions of adult rat bone marrow cells; and that this effect can be prevented by neutralization with Thy-1 antigen. It is not clear, however, that the suppression of CFU-S activity is due to reaction of anti-Thy-1 antibodies directly with CFU-S. Alternatively, the effect may be at the level of Thy-l-positive cells which regulate the proliferation of CFU-S, as demonstrated in the mouse (22, 23) . Assuming that anti-Thy-1 antibodies do react with CFU-S, it is possible that they do so nonspecifically by binding to Fc or complement receptors.
Results of experiments using the FACS show unequivocally that Thy-1 antigen is present on CFU-S. Thus, all CFU-S activity originally present in unseparated bone marrow cell suspensions was recovered in the Thy-1-positive cell population; whereas no CFU-S activity was present in the Thy-l-negative population. The use of F(abl)2 fragments of anti-Thy-1 antibodies precluded nonspecific reactions with Fc or complement receptors. It could be argued of course that hemopoietic stem cells have only trace amounts of Thy-1 antigen on their surface, and that one is dealing with a threshold phenomenon in a highly sensitive assay system. This is not the ease. Results of experiments in which Thy-l-positive bone marrow cells were separated according to relative fluorescence intensity (and hence relative amounts of Thy-1 antigen) indicate that CFU-S are among the most highly fluorescent subsets of cells. The results also indicate that if accessory cells exist in rat bone marrow, they too must be strongly positive for Thy-1 antigen.
Given that Thy-1 antigen is present on hemopoietic stem cells in adult rat bone marrow, it was of interest to determine if this was also true for stem cells in neonatal spleen and fetal liver. Stem cells in the latter tissues have been shown to differ significantly from stem cells in adult bone marrow with respect to physical characteristics and proliferative capacities (41) . The relationship between these two types of stem cells is not clear, but there is evidence to suggest that the former can give rise to the latter. The present experiments show that embryonic-type stern cells, like adulttype stem cells, are Thy-1 positive. CFU-S activity in suspensions of 16 day fetal liver cells was completely abrogated by treatment with rabbit anti-rat brain Thy-1 antiserum. At this stage of development, the majority of Thy-1 positive cells have the morphology of large, basophilic blast cells (18) .
Anti-Thy-1 serum also abrogated stem cell activity in suspensions of 3 day neonatal spleen cells as assayed by spleen colony formation and spleen weight gain. At less than saturating antibody dilutions (1:1,250 to 1:10,000) spleen weight gain after the injection of 1 × 107 treated cells was directly proportional to the dilution of antiThy-1 serum used. The slope of the resultant curve (Fig. 3) was identical to that formed by the injection of 5 × 105-1 × 10 7 untreated cells. The correspondence of these two dose-response curves strongly suggests that the anti-Thy-1 antibodies acted directly on the stem cells.
The proportions of rat lymphohemopoietic cells that were labeled by anti-Thy-1 sera in the present study are in good agreement with reported values (5, 6) , in particular the high percentage of Thy-l-positive cells in bone marrow (between 21 and 45% of nucleated cells), and the low percentages in lymph node and thoracic duet lymph (less than 10%) have been confirmed. In addition, most Thy-l-positive cells in rat bone marrow, spleen and thymus cortex were found to be cortisone sensitive. Assuming a frequency of 0.7 for pluripotent stem cells (42) and of 20% for Thy-l-positive cells, it is evident that the stem cells comprise a maximum of 3.5% of Thy-l-positive cells in rat bone marrow. Moreover, they appear to belong to a cortisone resistant subset of Thy-l-positive cells. 2 The identity of the remainder of the Thy-l-positive bone marrow cells is only partially known. Using an in vitro colony-forming unit assay (43), we have shown that progenitors of myeloid cells and of some B cells are Thy-1 positive. 20ntogenetic studies of Ig-positive cells also support the notion that immature members of the Bcell series are Thy-1 positive (18) . Moreover, Thy-l-positive bone marrow cells, isolated by the FACS, have been shown to generate B lymphocytes in irradiated recipients (17) . However, it is not possible to tell whether this was due to the transfer of pluripotent stem cells and/or B cell progenitors.
It also seems likely that Thy-1 antigen is present on thymocyte progenitors in the rat, but an independent marker for such ceils has yet to be identified in this species. One promising molecule in this respect is the enzyme terminal deoxynucleotidyl transferase (TdT), which in the rat is normally restricted to cortical thymocytes and to a small subset (1-4%) of cells in the bone marrow and prepubertal spleen (44) (45) (46) . 5 Several lines of evidence suggest that at least some of these could be thymocyte progenitors (46) (47) (48) fetal liver, neonatal spleen, and adult bone marrow were prevented from forming hemopoietic colonies in the spleens of irradiated recipients spleen (colony-forming unit assay) by incubation with antibodies to Thy-1 antigen. Highly specific rabbit heteroantiserum to purified rat brain Thy-1 antigen and mouse alloantisera to Thy-1.1-positive thymocytes were equally effective. This inhibition was neutralized by purified Thy-1 antigen.
In a second series of experiments, Thy-1-positive and Thy-l-negative populations of nucleated bone marrow cells were separated by the FACS. All of the hemopoietic stem cell activity was recovered in the Thy-1-positive population. The stem cells were among the most strongly positive for Thy-1 antigen, being in the upper 25th percentile for relative fluorescence intensity.
The relationships of Thy-1 antigen to the rat bone marrow lymphocyte antigen (BMLA) was shown in a third series of experiments. Rabbit anti-BMLA serum, which is raised against a null population of lymphocyte-like bone marrow cells, has been shown to have anti-stem cell activity. Here we demonstrate by double immunofluorescence, cocapping, and differential absorption studies that Thy-1 and BMLA are parts of the same molecule.
